Global Trastuzumab Emtansine for Injection Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Trastuzumab Emtansine for Injection market size was valued at US$ 325 million in 2024 and is forecast to a readjusted size of USD 517 million by 2031 with a CAGR of 6.9% during review period.
Trastuzumab emtansine was first approved by the U.S. Food and Drug Administration (FDA) in February 2013 for the treatment of HER2-positive, metastatic breast cancer in patients who have previously received trastuzumab and a taxane chemotherapy.
Trastuzumab emtansine has demonstrated significant benefits in the treatment of HER2-positive breast cancer, including improved progression-free survival and overall survival compared to standard treatments. Additionally, its targeted approach minimizes damage to healthy cells, reducing some of the side effects typically associated with traditional chemotherapy.
However, like any medical treatment, trastuzumab emtansine may cause side effects, including potential cardiac toxicity, liver problems, and adverse effects on the nervous system. Patients receiving this therapy should be carefully monitored by healthcare professionals.
Overall, trastuzumab emtansine represents an important advancement in the management of HER2-positive breast cancer and has provided new treatment options for patients who have previously received trastuzumab and taxane-based chemotherapy. The drug continues to be studied in clinical trials to explore its potential in various treatment settings and other cancer types.
This report is a detailed and comprehensive analysis for global Trastuzumab Emtansine for Injection market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Trastuzumab Emtansine for Injection market size and forecasts, in consumption value ($ Million), sales quantity (K L), and average selling prices (US$/L), 2020-2031
Global Trastuzumab Emtansine for Injection market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K L), and average selling prices (US$/L), 2020-2031
Global Trastuzumab Emtansine for Injection market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K L), and average selling prices (US$/L), 2020-2031
Global Trastuzumab Emtansine for Injection market shares of main players, shipments in revenue ($ Million), sales quantity (K L), and ASP (US$/L), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Trastuzumab Emtansine for Injection
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Trastuzumab Emtansine for Injection market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Genentech, Daiichi Sankyo, Amgen, Pfizer, Samsung Bioepis, Mylan(Viatris), Celltrion, Roche, Accord Healthcare, Nippon Kayaku, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Trastuzumab Emtansine for Injection market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
60mg
100mg
150mg
160mg
Others
Market segment by Application
Hospitals
Clinics
Others
Major players covered
Genentech
Daiichi Sankyo
Amgen
Pfizer
Samsung Bioepis
Mylan(Viatris)
Celltrion
Roche
Accord Healthcare
Nippon Kayaku
Chugai Pharmaceutical
Henlius
Orifarm
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Trastuzumab Emtansine for Injection product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Trastuzumab Emtansine for Injection, with price, sales quantity, revenue, and global market share of Trastuzumab Emtansine for Injection from 2020 to 2025.
Chapter 3, the Trastuzumab Emtansine for Injection competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Trastuzumab Emtansine for Injection breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Trastuzumab Emtansine for Injection market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Trastuzumab Emtansine for Injection.
Chapter 14 and 15, to describe Trastuzumab Emtansine for Injection sales channel, distributors, customers, research findings and conclusion.
Trastuzumab emtansine was first approved by the U.S. Food and Drug Administration (FDA) in February 2013 for the treatment of HER2-positive, metastatic breast cancer in patients who have previously received trastuzumab and a taxane chemotherapy.
Trastuzumab emtansine has demonstrated significant benefits in the treatment of HER2-positive breast cancer, including improved progression-free survival and overall survival compared to standard treatments. Additionally, its targeted approach minimizes damage to healthy cells, reducing some of the side effects typically associated with traditional chemotherapy.
However, like any medical treatment, trastuzumab emtansine may cause side effects, including potential cardiac toxicity, liver problems, and adverse effects on the nervous system. Patients receiving this therapy should be carefully monitored by healthcare professionals.
Overall, trastuzumab emtansine represents an important advancement in the management of HER2-positive breast cancer and has provided new treatment options for patients who have previously received trastuzumab and taxane-based chemotherapy. The drug continues to be studied in clinical trials to explore its potential in various treatment settings and other cancer types.
This report is a detailed and comprehensive analysis for global Trastuzumab Emtansine for Injection market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Trastuzumab Emtansine for Injection market size and forecasts, in consumption value ($ Million), sales quantity (K L), and average selling prices (US$/L), 2020-2031
Global Trastuzumab Emtansine for Injection market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K L), and average selling prices (US$/L), 2020-2031
Global Trastuzumab Emtansine for Injection market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K L), and average selling prices (US$/L), 2020-2031
Global Trastuzumab Emtansine for Injection market shares of main players, shipments in revenue ($ Million), sales quantity (K L), and ASP (US$/L), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Trastuzumab Emtansine for Injection
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Trastuzumab Emtansine for Injection market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Genentech, Daiichi Sankyo, Amgen, Pfizer, Samsung Bioepis, Mylan(Viatris), Celltrion, Roche, Accord Healthcare, Nippon Kayaku, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Trastuzumab Emtansine for Injection market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
60mg
100mg
150mg
160mg
Others
Market segment by Application
Hospitals
Clinics
Others
Major players covered
Genentech
Daiichi Sankyo
Amgen
Pfizer
Samsung Bioepis
Mylan(Viatris)
Celltrion
Roche
Accord Healthcare
Nippon Kayaku
Chugai Pharmaceutical
Henlius
Orifarm
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Trastuzumab Emtansine for Injection product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Trastuzumab Emtansine for Injection, with price, sales quantity, revenue, and global market share of Trastuzumab Emtansine for Injection from 2020 to 2025.
Chapter 3, the Trastuzumab Emtansine for Injection competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Trastuzumab Emtansine for Injection breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Trastuzumab Emtansine for Injection market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Trastuzumab Emtansine for Injection.
Chapter 14 and 15, to describe Trastuzumab Emtansine for Injection sales channel, distributors, customers, research findings and conclusion.
Table of Contents
107 Pages
- 1 Market Overview
- 2 Manufacturers Profiles
- 3 Competitive Environment: Trastuzumab Emtansine for Injection by Manufacturer
- 4 Consumption Analysis by Region
- 5 Market Segment by Type
- 6 Market Segment by Application
- 7 North America
- 8 Europe
- 9 Asia-Pacific
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
